| Literature DB >> 32139445 |
Barbara Katharina Hasse1, Isabelle Schmitt-Opitz2, Olivia Lauk3, Rosamaria Fulchini4.
Abstract
Here we present a rare combination of aortobronchial fistula and Listeria endograft infection after repeat endovascular aortic repair. Device retention, debridement and negative pressure wound therapy, in combination with suppressive antimicrobial therapy, led to satisfactory control of infection until the patient died due to another complication. The combination of an aortobronchial fistula and Listeria endograft infection has never been described before. This present case should encourage and show clinicians the importance of an interdisciplinary approach in highly difficult clinical courses. © BMJ Publishing Group Limited 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: drugs: infectious diseases; infections; interventional cardiology; medical management; vascular surgery
Year: 2020 PMID: 32139445 PMCID: PMC7059411 DOI: 10.1136/bcr-2019-229924
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X
Figure 1Initial computed tomography (CT) scan in 2015 with infected aneurysm bag (blue arrow).
Figure 2Vacuum sealing/black sponge (green arrow) was placed in the partial resected aneurysm bag and covered up with xenopericardial patch (blue arrow). The images on the top left and right, as well as the bottom left image, the diaphragm and the lung, retracted with the hook, are shown.
Figure 3Six-month follow-up without signs of an infected aneurysm bag (left image) compared with the previously infected aneurysm bag (right image).
Reported aortic endograft infections due to Listeria monocytogenes
| Patients (n) | Gender | Age | Location | Time after surgery | Surgical treatment | Medical treatment | Follow-up | Outcome | |
| Saleem | 1 | Male | 61 | EVAR | 7 months | Conservative. | Amoxicillin/clavulanic acid, | 1 year and 7 months | Alive |
| Heikkinen | 1 | Male | 77 | EVAR | Not stated | In situ reconstruction with complete removal of the infected stent. | Not stated. | 10 months | Alive |
| Cernohorsky | 1 | Not stated | Not stated | EVAR | Not stated | Conservative. | Amoxicillin/clavulanic acid, | Not stated | Alive |
| Tanner-Steinmann and Boggian | 1 | Male | 51 | EVAR | 2 years | Not stated. | Not stated. | Not stated | Not stated |
| Silvestri and Isernia | 1 | Female | 72 | TEVAR | 7 years | Conservative. | Cotrimoxazole/gentamicin. | 10 days | Died |
| Heysell 2016 | 1 | Female | 68 | TEVAR | 2 years | Conservative. | Ampicillin/gentamicin intravenously, | 3 years | Alive |
| Yamamoto | 1 | Male | 82 | EVAR | 14 months | In situ reconstruction with partial removal of the infected stent. | Vancomycin, meropenem, amoxicillin per os. | 30 months | Alive |
| Present case | 1 | Male | 70 | TEVAR | 10 years | Fistula resection, patch repair, debridement, negative pressure wound therapy and graft preservation. | Amoxicillin/clavulanic acid, gentamicin at the start of treatment. | 2 years and 4 months | Died |
EVAR, endovascular aortic repair; TEVAR, thoracic endovascular aortic repair.